Identification of tumor antigens that elicit a humoral immune response in breast cancer patients' sera by serological proteome analysis (SERPA)

Bechr Hamrita, Karim Chahed, Maria Kabbage, Christelle Lemaitre Guillier, Mounir Trimeche, Anouar Chaïeb, Lotfi Chouchane

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Background: In this study we applied a serological proteomics-based approach (SERPA) to identify tumor antigens that commonly induce a humoral immune response in patients with infiltrating ductal breast carcinomas. Methods: Sera obtained at the time of diagnosis from 40 patients with invasive breast cancer and 42 healthy controls were screened individually for the presence of IgG antibodies to MCF-7 cell line proteins. Immunoreactive proteins were isolated and subsequently identified by MALDI-TOF mass spectrometry. Results: We identified 26 proteins that reacted with antibodies in the sera from breast cancer patients. Among these antigens, a significantly higher frequency occurs against the molecular chaperone HSP60, the tumor suppressor prohibitin, β-tubulin, the haptoglobin-related protein and peroxiredoxin-2. Immunoreactivity to hnRNPK, Mn-SOD and F1-ATPase was also clearly detected in the patients group, whereas scarcely in control sera. By contrast, two other antigens identified as cytokeratins 8 and 18, as well as, F1-actin were found to elicit humoral immune responses in both control and breast cancer patients' sera. Conclusions: The immunoproteomic approach implemented here offers a powerful tool for determining novel tumor antigens that elicit a humoral immune response in patients with invasive breast cancer. These antigens and/or their related circulating antibodies may display clinical usefulness as potential diagnostic markers and provide a means for a better understanding of the molecular mechanisms underlying breast cancer development.

Original languageEnglish
Pages (from-to)95-102
Number of pages8
JournalClinica Chimica Acta
Volume393
Issue number2
DOIs
Publication statusPublished - 17 Jul 2008
Externally publishedYes

Fingerprint

Neoplasm Antigens
Proteome
Humoral Immunity
Breast Neoplasms
Serum
Antigens
Antibodies
Proteins
Keratin-8
Keratin-18
Peroxiredoxins
Molecular Chaperones
Haptoglobins
Proton-Translocating ATPases
Tubulin
Superoxide Dismutase
Carcinoma, Ductal, Breast
Mass spectrometry
Actins
Tumors

Keywords

  • Autoantibody
  • Infiltrating ductal carcinomas
  • Serological proteome analysis
  • Tumor antigen

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry

Cite this

Identification of tumor antigens that elicit a humoral immune response in breast cancer patients' sera by serological proteome analysis (SERPA). / Hamrita, Bechr; Chahed, Karim; Kabbage, Maria; Guillier, Christelle Lemaitre; Trimeche, Mounir; Chaïeb, Anouar; Chouchane, Lotfi.

In: Clinica Chimica Acta, Vol. 393, No. 2, 17.07.2008, p. 95-102.

Research output: Contribution to journalArticle

Hamrita, Bechr ; Chahed, Karim ; Kabbage, Maria ; Guillier, Christelle Lemaitre ; Trimeche, Mounir ; Chaïeb, Anouar ; Chouchane, Lotfi. / Identification of tumor antigens that elicit a humoral immune response in breast cancer patients' sera by serological proteome analysis (SERPA). In: Clinica Chimica Acta. 2008 ; Vol. 393, No. 2. pp. 95-102.
@article{fd7e18e2dc9b4d149a0411051d7637e6,
title = "Identification of tumor antigens that elicit a humoral immune response in breast cancer patients' sera by serological proteome analysis (SERPA)",
abstract = "Background: In this study we applied a serological proteomics-based approach (SERPA) to identify tumor antigens that commonly induce a humoral immune response in patients with infiltrating ductal breast carcinomas. Methods: Sera obtained at the time of diagnosis from 40 patients with invasive breast cancer and 42 healthy controls were screened individually for the presence of IgG antibodies to MCF-7 cell line proteins. Immunoreactive proteins were isolated and subsequently identified by MALDI-TOF mass spectrometry. Results: We identified 26 proteins that reacted with antibodies in the sera from breast cancer patients. Among these antigens, a significantly higher frequency occurs against the molecular chaperone HSP60, the tumor suppressor prohibitin, β-tubulin, the haptoglobin-related protein and peroxiredoxin-2. Immunoreactivity to hnRNPK, Mn-SOD and F1-ATPase was also clearly detected in the patients group, whereas scarcely in control sera. By contrast, two other antigens identified as cytokeratins 8 and 18, as well as, F1-actin were found to elicit humoral immune responses in both control and breast cancer patients' sera. Conclusions: The immunoproteomic approach implemented here offers a powerful tool for determining novel tumor antigens that elicit a humoral immune response in patients with invasive breast cancer. These antigens and/or their related circulating antibodies may display clinical usefulness as potential diagnostic markers and provide a means for a better understanding of the molecular mechanisms underlying breast cancer development.",
keywords = "Autoantibody, Infiltrating ductal carcinomas, Serological proteome analysis, Tumor antigen",
author = "Bechr Hamrita and Karim Chahed and Maria Kabbage and Guillier, {Christelle Lemaitre} and Mounir Trimeche and Anouar Cha{\"i}eb and Lotfi Chouchane",
year = "2008",
month = "7",
day = "17",
doi = "10.1016/j.cca.2008.03.017",
language = "English",
volume = "393",
pages = "95--102",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Identification of tumor antigens that elicit a humoral immune response in breast cancer patients' sera by serological proteome analysis (SERPA)

AU - Hamrita, Bechr

AU - Chahed, Karim

AU - Kabbage, Maria

AU - Guillier, Christelle Lemaitre

AU - Trimeche, Mounir

AU - Chaïeb, Anouar

AU - Chouchane, Lotfi

PY - 2008/7/17

Y1 - 2008/7/17

N2 - Background: In this study we applied a serological proteomics-based approach (SERPA) to identify tumor antigens that commonly induce a humoral immune response in patients with infiltrating ductal breast carcinomas. Methods: Sera obtained at the time of diagnosis from 40 patients with invasive breast cancer and 42 healthy controls were screened individually for the presence of IgG antibodies to MCF-7 cell line proteins. Immunoreactive proteins were isolated and subsequently identified by MALDI-TOF mass spectrometry. Results: We identified 26 proteins that reacted with antibodies in the sera from breast cancer patients. Among these antigens, a significantly higher frequency occurs against the molecular chaperone HSP60, the tumor suppressor prohibitin, β-tubulin, the haptoglobin-related protein and peroxiredoxin-2. Immunoreactivity to hnRNPK, Mn-SOD and F1-ATPase was also clearly detected in the patients group, whereas scarcely in control sera. By contrast, two other antigens identified as cytokeratins 8 and 18, as well as, F1-actin were found to elicit humoral immune responses in both control and breast cancer patients' sera. Conclusions: The immunoproteomic approach implemented here offers a powerful tool for determining novel tumor antigens that elicit a humoral immune response in patients with invasive breast cancer. These antigens and/or their related circulating antibodies may display clinical usefulness as potential diagnostic markers and provide a means for a better understanding of the molecular mechanisms underlying breast cancer development.

AB - Background: In this study we applied a serological proteomics-based approach (SERPA) to identify tumor antigens that commonly induce a humoral immune response in patients with infiltrating ductal breast carcinomas. Methods: Sera obtained at the time of diagnosis from 40 patients with invasive breast cancer and 42 healthy controls were screened individually for the presence of IgG antibodies to MCF-7 cell line proteins. Immunoreactive proteins were isolated and subsequently identified by MALDI-TOF mass spectrometry. Results: We identified 26 proteins that reacted with antibodies in the sera from breast cancer patients. Among these antigens, a significantly higher frequency occurs against the molecular chaperone HSP60, the tumor suppressor prohibitin, β-tubulin, the haptoglobin-related protein and peroxiredoxin-2. Immunoreactivity to hnRNPK, Mn-SOD and F1-ATPase was also clearly detected in the patients group, whereas scarcely in control sera. By contrast, two other antigens identified as cytokeratins 8 and 18, as well as, F1-actin were found to elicit humoral immune responses in both control and breast cancer patients' sera. Conclusions: The immunoproteomic approach implemented here offers a powerful tool for determining novel tumor antigens that elicit a humoral immune response in patients with invasive breast cancer. These antigens and/or their related circulating antibodies may display clinical usefulness as potential diagnostic markers and provide a means for a better understanding of the molecular mechanisms underlying breast cancer development.

KW - Autoantibody

KW - Infiltrating ductal carcinomas

KW - Serological proteome analysis

KW - Tumor antigen

UR - http://www.scopus.com/inward/record.url?scp=44449130082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44449130082&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2008.03.017

DO - 10.1016/j.cca.2008.03.017

M3 - Article

VL - 393

SP - 95

EP - 102

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 2

ER -